Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The venture arm of Baxter has teamed with Velocity Pharmaceutical Development (VPD) and the Mayo Clinic to launch Vitesse Biologics, a collaboration to develop antibody- and protein-based therapeutics. Each partner will play a role in the drug development process. VPD will identify drug targets, pick early-stage molecules, and take on preclinical studies. Mayo will conduct Phase I trials of drug candidates, and Baxter BioScience will contribute manufacturing and commercialization capabilities. Baxter BioScience, which will soon be spun off into a stand-alone company called Baxalta, will have an exclusive option to acquire any product developed by Vitesse after Phase I studies are complete.
This article has been sent to the following recipient: